Gemini Holdings, the company that launched a genetic database project in Newfoundland and Labrador, Canada this month, is to be floated on the stock market. The Nasdaq flotation is likely to value the company at more than $200 million.
Meanwhile, the value of PPL Therapeutics' shares rose this week, following it's announcement of plans to build a new plant in Scotland. The firm, which cloned Dolly the sheep, will use the new facility to extract a protein called alpha-1-antitrypsin from the milk of genetically altered sheep. It will take three years to build the plant and secure regulatory approval.
Celera Genomics, the firm racing to sequence the human genome, is now said to be contemplating a human 'proteome' project. The ambitious aim of the project would be to identify the properties and functions of every single human protein. Celera is in advanced discussions with GeneBio, the commercial arm of the Swiss Institute of Bioinformatics.
Sources and References
Dolly creates 150 jobs
Celera in talks to launch private sector human proteome project
Gemini to float on Nasdaq for $200m